FDA · DEA · state legislation · enforcement actions · clinical trial readouts · shortage designations. Updated daily by our research team.
One of the largest research-chemical vendors ceased US operations following FDA cease-and-desist. Active orders paused; existing customers advised to request batch COAs for materials already shipped.
AB-2847 would require in-state licensing for any telehealth prescriber of compounded medications. Would affect ~12 clinics currently operating in CA via out-of-state Rx networks.
FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. First prescription medication indicated specifically for OSA.
FDA removed semaglutide from the drug shortage list, ending 503A/503B compounding eligibility. Compounded semaglutide no longer lawfully produced as of Nov 22, 2025.
DEA and FDA executed warrants at Amino Asylum's Florida warehouse. Research-chemical sales paused; customer COA history inaccessible for 3 weeks post-raid.